Skip to main content
SpringerLink
Log in

Safety of secukinumab in psoriasis patients with latent tuberculosis infection

  • Correspondence
  • Published:
European Journal of Dermatology

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2020; 34: 1449–56.

    Article  CAS  Google Scholar 

  2. Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 2018; 379: 440–53.

    Article  CAS  Google Scholar 

  3. Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatmnt of psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1676–84.

    Article  CAS  Google Scholar 

  4. Shu C-C, Lee C-H, Lee M-C, Wang J-Y, Yu C-J, Lee L-N. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis 2013; 17: 934–9.

    Article  Google Scholar 

  5. Segueni N, Tritto E, Bourigault M-L, et al. Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNF α neutralization. Sci Rep 2016; 6: 36923.

    Article  CAS  Google Scholar 

  6. Kammüller M, Tsai T-F, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol 2017; 6: e152.

    Article  Google Scholar 

  7. Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol 2019; 11: 23–8.

    Article  Google Scholar 

  8. Romiti R, Valenzuela F, Chouela EN, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis. Br J Dermatol 2019; 181: 202–3.

    Article  CAS  Google Scholar 

  9. Skyrizi: EPAR — product information. Available at: https://www.ema.uropa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf.

  10. Discussed E-Poster Presentations. J Eur Acad Dermatol Venereol 2019; 33: 20–44.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Centro Hospitalar Universit ário do Porto, Porto, Portugal

    Álvaro Machado & Tiago Torres

  2. Department of Infectious Diseases, Centro Hospitalar Universit ário do Porto, Porto, Portugal

    Miguel Abreu

  3. Instituto de Ci ências Biomédicas Abel Salazar, University of Porto, Porto, Portugal

    Miguel Abreu & Tiago Torres

Authors
  1. Álvaro Machado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miguel Abreu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tiago Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tiago Torres.

Additional information

Disclosure

Funding sources: none. Conflicts of interest: Alvaro Machado and Miguel Abreu have no conflicts of interest to declare. Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Biocad, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme and Sandoz.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Machado, Á., Abreu, M. & Torres, T. Safety of secukinumab in psoriasis patients with latent tuberculosis infection. Eur J Dermatol 30, 740–741 (2020). https://doi.org/10.1684/ejd.2020.3909

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2020.3909

Search

Navigation